linjc16/ctgov huggingface dataset:
Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether S-1 and oxaliplatin as neoadjuvant chemotherapy may improve survival benefit compared with control.

Official Title
-----------------
Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: Drug: S-1 and oxaliplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DISEASE CHARACTERISTICS: Histologically confirmed gastric adenocarcinoma Locally advanced disease:Clinical stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification) Planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy Age:20 to 75 Performance status:ECOG 0-2 Life expectancy:Not specified Hematopoietic:WBC 4,000-12,000/mm^3；Granulocyte count ≥ 2,000/mm^3；Platelet count ≥ 100,000/mm^3；Hemoglobin ≥ 9.0 g/dL;Hepatic:AST and ALT ≤ 100 U/L；Bilirubin ≤ 1.5 mg/dL Adequate organ function Able to swallow oral medication Written informed consent Exclusion Criteria: Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ Pregnant or breast-feeding women Severe mental disease Systemic administration of corticosteroids, flucytosine, phenytoin or warfarin Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, or ischemic heart disease Myocardial infarction within six disease-free months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drug:S-1:80mg/m2;oxaliplatin 130mg/m2<br>Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy | Drug: Drug: S-1 and oxaliplatin<br>* Drug:S-1:80mg/m2;oxaliplatin 130mg/m2<br>* Other names: Oxaliplatin：sanofi-aventis;|
| No Intervention: surgery<br>Procedure/Surgery: Gastrectomy with D2 dissection | Drug: Drug: S-1 and oxaliplatin<br>* Drug:S-1:80mg/m2;oxaliplatin 130mg/m2<br>* Other names: Oxaliplatin：sanofi-aventis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response rate |  | 3 months |
Contrast-Enhanced US of Spleen, Liver and Kidney

Study Overview
=================
Brief Summary
-----------------
To evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional US with continuous infusion of a contrast agent (SonoVue, Bracco, Italy). Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.

Detailed Description
-----------------
To evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional US with continuous infusion of a contrast agent (SonoVue, Bracco, Italy). Three cohortes will be studied: cohorte 1 infection at Plasmodium falciparum (24 patients), cohorte 3 infection at Plasmodium vivax, ovale or malariae (5 patients) and cohorte 2 other infectious diseases such as acute pyelonephritis (24 patients). Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.

Official Title
-----------------
Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study

Conditions
-----------------
Malaria, Pyelonephritis, Bacterial Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Social security number Age over 18 acute malaria infection or other infectious diseases Inpatients Signed informed consent form Exclusion Criteria: Pregnancy Criteria of bad tolerance of infection Treatment started for more than 8 hours Lack of cooperation History of splenectomy, hematological disease, cirrhosis with portal hypertension, splenomegaly Medical treatment with beta blocker, diuretic, immunodepression drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FUNCTIONAL STUDY, CONTRAST-ENHANCED US, PERFUSION
Inter-observer Variation in Gross Tumor Delineation of Esophageal Cancer on MR, CT and PET CT

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate inter-observer variation in gross tumor volume (GTV) delineation of oesophageal cancer on different imaging modalities - CT, PET CT and MR.Twenty-three consecutive patients with esophageal cancer treated with preoperative or curative chemoradiotherapy were selected. All patients had CT, PET CT and MR imaging in treatment position prior to radiotherapy.Five experienced observers from our institution will independently delineate GTV on CT alone, MR alone, PET CT alone, on co-registered CT and MR and co-registered PET CT and MR. Inter-observer agreement, expressed in generalized conformity index (CIgen) and mean volumes of GTV will be calculated per patient and imaging modality.

Official Title
-----------------
Inter-observer Variation in Gross Tumor Delineation of Esophageal Cancer on MR, CT and PET CT

Conditions
-----------------
Esophageal Cancer

Intervention / Treatment
-----------------
* Other: MR, PET CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: locally advanced esophageal cancer eligible for treatment with preoperative or curative chemoradiotherapy Exclusion Criteria: contraindications for MR

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MR, PET CT|diagnostic method|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of interobserver variability in target volume delineation on CT, PET CT and MR. | To compare target volume delineation of esophageal cancer using CT, PET CT and MR with determining generalized conformity indexes and mean volumes of GTV. | Through study completion, an average of 1 year. |
Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in Cardiac Resynchronisation Therapy (CRT) Patients

Study Overview
=================
Brief Summary
-----------------
It's the aim of this study to analyse efficacy and reliability of VectSelect Feature for avoidance of phrenic nerve stimulation in cardiac resynchronisation therapy (CRT) patients.

Official Title
-----------------
Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in CRT Patients

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for CRT-D implantation / upgrade written informed consent Exclusion Criteria: pregnancy age < 18 years patients, who cannot visit the routine follow ups (within first 3.5months) participants to other studies with active treatment arm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of patients with at least one acceptable LV pacing configuration. | Amount of patients with at least one acceptable, programmable LV pacing configuration. Definition of acceptable LV pacing configuration: LV pacing threshold <=2.5V@0.5ms AND Phrenic nerve threshold is at least twice as high as LV pacing threshold AND LV pacing impedance >=200 Ohms. Only patients with implanted CRT-D and bipolar leftventricular lead are taken into account. | First Follow Up after hospital discharge (approx. 1-3 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CRT, Phrenic nerve stimulation, LV pacing configuration, Cardiac resynchronisation therapy, Heart failure
Swiss Multiple Sclerosis Cohort-Study

Study Overview
=================
Brief Summary
-----------------
The key aims of the Swiss Multiple Sclerosis Cohort-Study (SMSC) are To maintain a long-term cohort (>10 years) representative of the MS population currently living in Switzerland. This requires effective measures to limit drop-outs and the continuous recruitment of MS patients and To conduct a systematic follow-up with standardized, high quality collection of clinical and magnetic resonance imaging (MRI) data, as well as body fluids. The significant heterogeneity within the diagnostic entity and phenotype of multiple sclerosis (MS) is incompletely understood. A central and necessary prerequisite of further advance is a sufficient amount of high quality clinical and paraclinical (imaging, body fluids) patient data. Nested projects will address specific research topics, and facilitate collaboration of the most qualified investigators within the group of SMSC investigators. The nested projects will focus on the: Development and validation of diagnostic and prognostic markers of spontaneous disease evolution and therapeutic response. Exploration of the safety and impact on long-term disability of existing and next generation MS treatments Individualized therapy: A number of highly active but potentially also harmful therapies have lately been established for the treatment of MS. To date, due to the lack of individual prognostic markers patients may not receive aggressive therapy due to safety concerns, or patients with benign disease may receive expensive and potentially harmful treatments without the need for it.

Official Title
-----------------
Swiss Multiple Sclerosis Cohort-Study: A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: without immunomodulatory treatment (DMD) or starting a DMD already treated with Tysabri® or Gilenya® switching a DMD or indication for switching DMD.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in assessment of Expanded Disability Status Scale (EDSS) | assessment of Expanded Disability Status Scale | every 6 or 12 months, up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MS key phases of disease evolution, MS New Treatment Options
MRI Perfusion in Adnexal Masses

Study Overview
=================
Brief Summary
-----------------
As ovarian cancer is characterized by an anarchic neovascularization resulting in a wide number of immature microvessels. These vessels are characterized by a lack of coverage by pericytes and the higher expression of one of the receptors of Vascular Endothelial Growth Factor on both endothelial and epithelial cells of ovarian cystadenocarcinomas. These physio pathogenic characteristics have been demonstrated to be in line with variations of MR perfusion parameters. Unlike many lesions that occur in other parts of the body, biopsy should not be performed in adnexal masses that demonstrate no evidence of peritoneal disease because it may cause spillage of cystic contents, potentially leading to iatrogenic up-staging of what may have been a malignant tumor that was limited.

Official Title
-----------------
Added Value of MRI Perfusion in Evaluation of Complex Adnexal Masses

Conditions
-----------------
Complex Adnexal Masses

Intervention / Treatment
-----------------
* Device: MRI perfusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: complex adnexal mass patient fit for surgery Exclusion Criteria: any general contraindication to MRI severely ill patients those with claustrophobia.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detect the number of malignant adnexal masses |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diagnosis
Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)

Study Overview
=================
Brief Summary
-----------------
The aim of Alizé is to describe a population of premature babies (gestational age (GA) < 32 weeks) in real life situation and the management of RDS.

Detailed Description
-----------------
Description includes gestational age, birth clinical characteristics in particular the respiratory function, evaluation of the mother prenatal corticosteroids treatment in prophylaxis of RDS, mother medical and obstetric history, premature babies care in the delivery room with a special focus on the Curosurf use: prophylactic or curative use / other surfactant / no surfactant. A special focus is on the Prophylactic use.

Official Title
-----------------
Observational Study in Neonatal Intensive Care Units (NICU) on the Real Life Use of Curosurf in Prophylaxis of RDS in Premature Babies.

Conditions
-----------------
Respiratory Distress Syndrome, Newborn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: during the study, each neonatologist will have to include all the babies born with a gestational age < 32 GA Exclusion Criteria: gestational age > 32 GA No consent to the data collection by one of the parents

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 12 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Premature babies < 28 GA<br> | |
| Premature babies > 28 & < 32 weeks GA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulmonary surfactant, Respiratory distress syndrome, Newborn, prophylaxis
Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction

Study Overview
=================
Brief Summary
-----------------
This study is an evaluation of the survival of the implants and bridges, quality of prosthetic work and patient satisfaction after immediate loading of the implants in a totally edentate upper and lower jaw.

Detailed Description
-----------------
This study is an evaluation of the survival of the implants and bridges, quality of prosthetic work and patient satisfaction after immediate loading of the implants in a totally edentate upper and lower jaw.

Official Title
-----------------
Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. A Retrospective Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction

Conditions
-----------------
Dental Implants

Intervention / Treatment
-----------------
* Procedure: Immediate loading of implants in totally edentate upper and lower jaw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-90 years old Exclusion Criteria: Medical risk patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: implants<br> | Procedure: Immediate loading of implants in totally edentate upper and lower jaw<br>* Immediate loading of implants in totally edentate upper and lower jaw.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of implants and bridges |  | At beginning until last follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of prosthetic work |  | At end of follow up | 
| Patient satisfaction |  | At end of follow up. |
A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral vorinostat in patients with malignant lymphoma.

Official Title
-----------------
A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Drug: vorinostat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who relapsed after complete or partial response, or ineffective in previous chemotherapy Exclusion Criteria: Patients with history of chemotherapy, antibody therapy, radiotherapy, during the previous 4 weeks (6 months for radioisotope-labeled antibody) Any uncontrolled concomitant illness Are pregnant or breast-feeding Serious drug or food allergy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vorinostat<br>Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest. | Drug: vorinostat<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants Experiencing Dose-Limiting Toxicities (DLTs) |  | Up to 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under the Curve (AUC) of Vorinostat After Single Oral Dosing |  | Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose on Days 1 and 17 |
The Predictors of the Neonatal Hyperbilirubinemia

Study Overview
=================
Brief Summary
-----------------
The oxygen tension increases more than 3 times from fetus to neonate. The oxidant stress happens. And it will cause the destruction of RBC. So, we propose that the ROS may play an important role of neonatal hyperbilirubinemia. There is strong association between the bilirubin level and ROS levels at 3 days old in our pilot study.

Detailed Description
-----------------
The incidence of neonatal jaundice is higher in Eastern population than western people. The bilirubin comes from the destruction of RBC which heme is released and catabolized. If the bilirubin enters into the brain and deposits in basal ganglion, it will cause apoptosis of the neuronal cells, that is so called kernictrus, which is the major complication of the neonatal jaundice. However, the bilirubin has its own antioxidant protective effect. Many clinical or basic studies tried to find out the relationship of bilirubin and reactive oxygen species (ROS) in recent years. The American Association of Pediatrics proposed the management principle of neonatal jaundice in 1994. It postponed the management criteria of neonatal jaundice Besides, early discharge (before 48 hour-old) was the trend in many countries. It may be dangerous because the neonatal jaundice appears after 48 hour-old. Whether the criteria and the trend will cause the elevation of the incidence of kernictrus, is always the major concern of clinicians. So, searching factors to predict neonatal hyperbilirubinemia causes the interest of many investigators. The predictors are divided into risk-factor based and normogram based. But they are still not suitable for all populations.

Official Title
-----------------
The Predictors of the Neonatal Hyperbilirubinemia

Conditions
-----------------
Hyperbilirubinemia, Neonatal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health neonate Exclusion Criteria: perinatal insults prematurity

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
free radicals, hyperbilirubinemia, Health neonate